Last Updated : May 14, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort ascending | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Saxenda | liraglutide | Chronic weight management in adults | Do not reimburse | Complete | ||
Venclexta | venetoclax | Acute myeloid leukemia | Do not reimburse | Complete | ||
Tecentriq & Avastin | Atezolizumab & Bevacizumab | NSQ-NSCLC | Do not reimburse | Complete | ||
Corzyna | ranolazine | Stable angina pectoris, adults | Do not reimburse | Complete | ||
Zeposia | ozanimod | Multiple Sclerosis, relapsing - remitting | Do not reimburse | Complete | ||
Cablivi | caplacizumab | Acquired thrombotic thrombocytopenic purpura (aTTP) | Do not reimburse | Complete | ||
Tafinlar & Mekinist in combo | Dabrafenib & Trametinib in combo | Non-Small Cell Lung Cancer | Do not reimburse | Complete | ||
Yondelis | Trabectedin | Metastatic Liposarcoma or Leiomyosarcoma | Do not reimburse | Complete | ||
Orkambi | lumacaftor/ivacaftor | Cystic Fibrosis, F508del CFTR mutation | Do not reimburse | Complete | ||
Zykadia | Ceritinib | Metastatic Non-Small Cell Lung Cancer | Do not reimburse | Complete |